ZYUS Life Sciences Raises C$50,000 in Second Tranche of Unit Offering

ZYUS Life Sciences Corporation closed the second tranche of a non-brokered private placement, issuing 111,110 units at C$0.45 each for C$50,000 in gross proceeds. Newswire published the announcement on November 6, 2026.

How the ZYUS Unit Offering Is Structured

The offering covers up to 6,666,666 units for aggregate gross proceeds of up to C$3,000,000. Each unit consists of one common share and one-half of one common share purchase warrant, with each whole warrant exercisable at C$0.59 for twenty-four months from issuance. The first tranche closed on October 21, 2026, and the two tranches together raised approximately $0.25 million. ZYUS said it expects to close an additional tranche shortly and will use the proceeds for general corporate and working capital purposes.

Certain insiders of ZYUS purchased all of the 111,110 units sold in the second tranche. The company described the insider participation as a related party transaction under Multilateral Instrument 61-101 and said it relied on exemptions from formal valuation and minority shareholder approval requirements because it is not listed on a stock exchange specified in section 5.5(b) and neither the fair market value of the securities issued to insiders nor the consideration paid exceeds $2.2 million. The directors approved the offering unanimously. No finders' fees were paid in connection with the second tranche, and the securities carry a hold period expiring March 7, 2027.

ZYUS's Earlier Private Placement and Debt Raises

According to akta.pro company records, ZYUS has 18 funding rounds on record and total funding of $44.2 million, with the last round dated October 21, 2026. The records list a March 2026 first tranche of a non-brokered private placement that raised approximately C$284,300 through 451,269 units at C$0.63 each, and a February 2026 placement launched to raise up to C$7 million through up to 11,111,111 units at C$0.63 per unit.

ZYUS's Path From First Tranche to Second

On October 22, 2026, Newswire reported that ZYUS completed its first tranche of the non-brokered private placement, issuing 444,444 units at C$0.45 each for C$200,000 in gross proceeds. On September 9, 2026, Newswire reported that ZYUS announced reinstatement to trading on the TSXV and a working capital deficiency of $21.9 million as of June 30, 2026. On August 31, 2026, Newswire reported that ZYUS completed a secured loan financing with aggregate gross proceeds of CAD$1,945,000, secured by a general security agreement, bearing 12% interest and maturing six months from each tranche's effective date.

ZYUS's Remaining Approvals and Hold Period

The offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. All securities issued under the second tranche are subject to a hold period expiring March 7, 2027.